[Asia Economy Reporter Hyungsoo Park] NKMAX announced on the 10th that its subsidiary NKGENBIOTECH has been selected as an oral presenter at the "25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)." At ASGCT, NKMAX will present the proliferation and culture technology and efficacy of its NK cell therapy, SuperNK.


The American Society of Gene & Cell Therapy (ASGCT) is an association composed of members from the global bio industry, including the United States. It is the largest conference on the development and clinical application of gene and cell therapies, held annually. This year, it will take place from the 16th to the 19th of this month in Washington, USA.


The abstract includes the strengths of the culture technology that enhances NK cell activity in sarcoma clinical patients currently undergoing trials in the United States, as well as NKMAX's unique clinical technique that does not require lymphocyte depletion surgery. In the Cohort 1 clinical results, among 9 patients who failed treatment with existing therapies, 7 were confirmed to have stable disease (SD) where the tumor no longer grew with NK cell therapy alone. The disease control rate (DCR) was recorded at 77.8%.


This was expected to be the effect of the highly active SuperNK. NKMAX can proliferate and culture SuperNK with over 90% high activity. After isolating the patient's NK cells and culturing them with NKMAX's technology, the receptor expression rate rises above 90%. This leads to cancer cell killing ability, meaning it attacked cancer cells even in patients who were unresponsive to treatment.



An NKMAX official stated, "Using NK cells with low activity as a therapeutic agent makes it difficult to achieve efficacy, so technology to increase NK cell activity during the proliferation and culture process is necessary." They added, "SuperNK can maximize the activity of NK cells from cancer patients, which originally have low activity, during proliferation and culture, thus possessing excellent cancer-killing ability."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing